Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery. - Wikidata - wikimedia - TriplyDB

Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.

Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.

http://www.wikidata.org/entity/Q37404428

about

Soluble CD14 levels in plasma and breastmilk of Malawian HIV+ women: Lack of association with morbidity and mortality in their exposed infants.

P2860

Q47546312-D33DF9B1-998F-4A71-A1BA-80AE63B9CFDD

P2860

Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.

http://www.wikidata.org/entity/Q37404428

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@en

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@nl

type

label

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@en

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@nl

prefLabel

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@en

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@nl

P1433

Q37404428-330FD621-60FC-4385-A94A-2D6917D2378C

P1476

Q37404428-69E6F331-33BC-46BD-ACCC-BD37E49762D3

P2093

Q37404428-393941BB-3005-44B7-88C8-700A4FC6772B

Q37404428-53E12459-735D-4FE1-A598-F4B754722D9A

Q37404428-623A4E22-1BE8-4D57-9893-4B48F8012835

Q37404428-8EF59A0B-6399-4F6B-9DEE-E0796C76F3AF

Q37404428-9FBDEE97-B42A-4DFE-8C85-9D0CE8DE9FCB

Q37404428-A54602AF-D4BA-42F5-ACF3-76CEC7946215

Q37404428-DF454328-5734-45F9-AA6A-ACB810851DE9

P2860

Q37404428-0EC42EEA-617C-42AF-A0F7-AA5672FAF8F6

Q37404428-0F3F2116-7258-4993-80FC-884A8322CF42

Q37404428-18564A17-DF7D-4EDB-8BE0-C0FCBE2DE290

Q37404428-28E99399-D3A9-4D13-8F8A-EC7DE22E789E

Q37404428-2D769375-FF5E-4B13-B938-E16CCD526455

Q37404428-529DC254-7DE0-419C-906F-B490B7142858

Q37404428-89F01D12-423C-4EE2-BAF0-6176C8D9F45C

Q37404428-92D6228A-E626-4C0D-A1F2-02C9B48A19A9

Q37404428-96F28FC7-84B8-470F-AA66-EC9A329B3CAB

Q37404428-9F30BA4A-4224-4054-9E4F-CDC6815146C2

P304

Q37404428-A27472C7-278F-431F-A2B0-EBFE76418400

P31

Q37404428-F434DFEE-05BC-4DC1-8EDF-AB18C7C2F117

P356

Q37404428-C1B547C8-B8C3-4127-B7AC-1723940B5D7C

P407

Q37404428-2EC8E93A-57E0-488F-95CA-A49DDD852BF7

P433

Q37404428-2B09503A-2C24-4DDD-B88A-A3027D8CBBB7

P478

Q37404428-08A92CBB-11C8-4A11-A09E-1C1EDABFC7C1

P577

Q37404428-E1DB6F60-7818-45FE-8828-B1DC9581C435

P698

Q37404428-6653C844-00B0-46BF-87EB-E340A9B3465A

P921

Q37404428-2B04EDA8-2CA5-44E3-ACFA-EB4F81036E2F

Q37404428-4889F367-B7F3-4F63-9E54-C382BD50AFBD

Q37404428-C5FCBEAE-CD0E-4C81-8F23-2ED87B5F422B

Q37404428-E4B0D1D2-6567-4321-AF06-6A16253502A0

P932

Q37404428-ED57DDDD-02BC-43E0-9B8A-1ECDB4798351

P356

QAI.0B013E31829B0B9F

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Biomarkers from late pregnancy ...... oviral therapy after delivery.

@en

P2093

David E Shapiro

http://www.w3.org/2001/XMLSchema#string

Deborah Kacanek

http://www.w3.org/2001/XMLSchema#string

Erin Leister

http://www.w3.org/2001/XMLSchema#string

Jennifer S Read

http://www.w3.org/2001/XMLSchema#string

Judith S Currier

http://www.w3.org/2001/XMLSchema#string

Risa M Hoffman

http://www.w3.org/2001/XMLSchema#string

Yvonne Bryson

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

CD4+ count-guided interruption of antiretroviral treatment

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

Prevalent pregnancy, biological sex, and virologic response to antiretroviral therapy

D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed.

Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers

The immunology of successful pregnancy.

Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025

Immunologic activation during pregnancy: serial measurement of lymphocyte phenotype and serum activation molecules in HIV-infected and uninfected women.

Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.

P304

593-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E31829B0B9F

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23714738

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

postpartum period

P932

3868443

http://www.w3.org/2001/XMLSchema#string